TYBR Health
TYBR Health Raises $30M Series A for Surgical Healing Products
TYBR Health announced $30M in Series A financing on July 21, 2026. TYBR Health raised a $30 million Series A led by Vensana Capital and Mutual Capital Partners to expand commercial access to its FDA-cleared B3 GEL System.
Round details
The financing includes backing from Vensana Capital, Mutual Capital Partners, Neovate Capital Partners. The company did not publish a valuation with the announcement.
- Round: Series A
- Capital announced: $30M
- Headquarters: Houston, TX
How the company plans to use the capital
TYBR Health will expand commercial access to its FDA-cleared B3 GEL System, broaden its product indications, and run clinical studies evaluating tissue protection during orthopedic surgery.
Why this matters for GTM teams
The round points to investor interest in medical technology aimed at protecting healing tissue after surgery, with commercial expansion and clinical evidence both part of the plan.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: TYBR Health Series A announcement.
Company Info
Investors (3)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started